Core Insights - The company, Hongbo Pharmaceutical, has announced that its DiOrion platform has provided technical support for a total of 95 new drug projects as of August 2025 [1] - Out of these projects, 7 have entered the clinical trial phase, indicating progress in drug development [1] - The platform has served a total of 45 clients across multiple therapeutic areas, showcasing its broad applicability in the pharmaceutical industry [1] Platform Development - The DiOrion platform is a self-developed enabling platform for drug research and development, which has completed local deployment and is continuously iterating and upgrading [1] - It has integrated 9 core modules that cover the entire process of early-stage new drug development [1]

Core Viewpoint - Hongbo Pharmaceutical (301230) is enhancing its DiOrion platform to improve early-stage drug development capabilities, focusing on modular capabilities such as molecular design, virtual screening, drug-likeness assessment, and patent risk analysis [1] Group 1 - The company is developing its DiOrion platform to address key aspects of early drug research [1] - The focus areas include molecular design, virtual screening, drug-likeness assessment, and patent risk analysis [1] - The company aims to steadily advance the application of these technologies in pharmaceutical research to improve R&D efficiency and strengthen core competitiveness [1]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

Group 1 - Zhejiang Wenchuang Internet focuses on digital marketing and cultural technology, integrating AI into smart marketing and digital content creation, enhancing brand marketing digital transformation across various industries [1][17] - Saiwu Technology collaborates with Suzhou University to establish the AI4S laboratory, creating a closed loop of "AI screening - process optimization - mass production," significantly increasing revenue in related businesses [1][18] - Huashi Technology strategically invests in Yuchuang Robotics, applying AI in various scenarios such as airport monitoring and risk warning, providing intelligent solutions for smart cities [1][19] Group 2 - Yidian Tianxia leverages AI for global smart marketing, developing a full-chain solution that includes multi-language digital content generation and intelligent ad optimization [2][18] - Tongda Hai builds a comprehensive legal knowledge graph using vast legal data, enhancing judicial efficiency through its self-developed AI platform [2][19] - Sanwei Communication's subsidiary, Juwang Technology, utilizes AI for advertising material generation and optimization, significantly improving marketing efficiency [2][19] Group 3 - BlueFocus is a leader in AI marketing, applying AI across the entire marketing chain, including creative generation and effect analysis, to drive digital transformation in the marketing industry [3][19] - Huashu Media actively promotes AI integration in broadcasting, enhancing user experience through smart content recommendations and network optimization [3][20] - Subot constructs a cross-disciplinary platform for material and intelligent mechanics, driving high-end material development and optimizing production processes [3][20] Group 4 - Shiji Tianhong integrates AI into education, enhancing digital transformation in educational support services through intelligent systems [4][20] - Hongbo Pharmaceutical's AI drug design platform focuses on cyclic peptide drug development, significantly improving drug design efficiency and accuracy [5][21] - Tianlong Group's self-developed platform empowers digital marketing across various industries, enhancing customer acquisition and conversion rates [5][21] Group 5 - Yanshan Technology integrates AI into internet services and supply chain management, optimizing marketing and operational efficiency [6][22] - ChaoTu Software merges AI with GIS, enabling intelligent spatial data processing and analysis for smart city applications [6][22] - Heren Technology focuses on smart healthcare, developing AI systems to assist medical personnel and improve operational efficiency [6][23] Group 6 - Youzu Network applies AI throughout game development and operation, enhancing player engagement and experience [6][23] - Jinka Intelligent integrates AI into gas metering, improving management efficiency and safety in gas supply [7][24] - Liard incorporates AI into display technology, optimizing visual experiences and expanding applications in smart displays [7][24] Group 7 - Guanshang Technology focuses on military equipment lifecycle management using AI for fault diagnosis and training simulation [7][25] - Zhidema applies AI in consumer decision-making and e-commerce marketing, enhancing product recommendations and marketing strategies [7][25] - Runda Medical enhances laboratory testing processes with AI, improving detection accuracy and efficiency [7][25] Group 8 - Tiandi Online specializes in digital marketing, utilizing AI for user profiling and intelligent ad targeting [8][26] - Qianfang Technology focuses on smart transportation, developing AI systems for traffic management and vehicle recognition [8][26] - Jiaxun Feihong integrates AI into communication and rail transit, enhancing operational efficiency and safety [8][26] Group 9 - Jiadu Technology applies AI in smart city and rail transit, enhancing safety monitoring and automation [8][27] - Jiuzhoutong empowers pharmaceutical supply chains with AI for demand forecasting and inventory management [8][27] - Weining Health focuses on comprehensive smart healthcare solutions, enhancing operational efficiency and cost control [8][27] Group 10 - Dianke Digital strengthens IT service capabilities with AI, focusing on data center operations and security [8][28] - Guangting Information specializes in intelligent connected vehicles, developing AI systems for driving assistance and data governance [8][28] - Rongxin Culture integrates AI into children's publishing, enhancing reading experiences and content creation [8][29] Group 11 - Zhaochi Co. introduces AI in consumer electronics and lighting, optimizing product performance and supply chain management [8][29] - Jinxiandai focuses on industrial software, enhancing digital transformation through AI-assisted development and operations [8][30] - Huatu Shanding integrates AI into architectural design, improving efficiency and precision in building projects [8][30] Group 12 - Lakala enhances payment services with AI, improving transaction security and merchant support [8][30] - Yingjianke focuses on building design software, utilizing AI for structural optimization and efficiency [8][30] - Borui Communication empowers media and digital culture with AI, enhancing content delivery and user engagement [8][31] Group 13 - Haoyun Technology enhances security IoT with AI, providing risk assessment and decision support [8][31] - Shenguang Group leverages AI for digital marketing, optimizing user targeting and ad performance [8][31] - Oriental Pearl actively promotes AI in broadcasting, enhancing content production and user experience [8][31] Group 14 - Zhizhen Technology focuses on IT operations in communication and government sectors, utilizing AI for efficient management [8][32]

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Group 1 - The core viewpoint of the news is that the A-share market is seeing a strong performance in innovative drug concept stocks, driven by a policy encouraging the sale of innovative drugs and reference preparations in retail pharmacies [1] Group 2 - Guangshentang (300436) experienced a 20% increase, with a total market value of 15.3 billion and a year-to-date increase of 8% [2] - Zhongsan Co. (301093) rose by 12%, with a market capitalization of 13.8 billion and a year-to-date increase of 63.89% [2] - Hanshang Group (600774) saw a 10% increase, with a market value of 3.408 billion and a year-to-date increase of 26.37% [2] - Hite Bio (300683) increased by 7.92%, with a market capitalization of 4.371 billion and a year-to-date increase of 20.41% [2] - Bibete (688759) rose by 6.64%, with a market value of 24.9 billion and a year-to-date increase of 90.09% [2] - Shutaishen (300204) increased by 5.78%, with a market capitalization of 13.6 billion and a year-to-date increase of 4.58% [2] - Chengdu Xian Dao (688222) rose by 5.42%, with a market value of 13.8 billion and a year-to-date increase of 46.78% [2] - Haiwang Bio (000078) increased by 5.23%, with a market capitalization of 10.1 billion and a year-to-date increase of 10.40% [2] - Jiuzhoutong (600998) rose by 4.71%, with a market value of 28 billion and a year-to-date increase of 8.59% [2] - Hongbo Pharmaceutical (301230) increased by 4.60%, with a market capitalization of 6.76 billion and a year-to-date increase of 62.48% [2] - Huana Pharmaceutical (688799) rose by 4.09%, with a market value of 6.882 billion and a year-to-date increase of 9.87% [2]

Investment Rating - The industry investment rating is "Strong Buy" and is maintained [2]. Core Insights - The investment value of the AI + pharmaceutical industry lies in the analysis of the current state and future judgment of the industry. Understanding the role of AI in pharmaceuticals, its business models, growth potential, key growth factors, and competitive barriers is essential [4]. - AI in pharmaceuticals primarily enhances efficiency and innovation. The most mature applications of AI in drug development focus on cost reduction and efficiency improvements in preclinical stages, significantly shortening development cycles and reducing costs [5]. - The global market for AI-enabled drug development is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a CAGR of 22.6% [5]. - The industry has seen a significant increase in investment, with the AI + CRO/AI + Biotech model being a major trend for profitability. High-quality data production capabilities are identified as a core competitive advantage [5][6]. Summary by Sections AI's Role in Pharmaceuticals - AI in drug development combines technologies like NLP and deep neural networks to enhance efficiency and expand innovation space. It integrates vast biomedical data to empower the entire drug development process [9]. - AI's application is most effective in the preclinical research phase, where it can reduce costs by over 90% and significantly shorten development timelines [21]. Market Size and Commercialization Focus - The AI + pharmaceutical financing landscape has seen rapid growth since 2015, with a total of $24.6 billion raised by 2022. However, there has been a decline in financing activity due to global economic conditions [48]. - The commercial focus is on molecular entities, with the industry not yet forming a unified paradigm, leading to structural differentiation among companies [52][68]. Business Models - The industry features three main business models: SaaS, AI + CRO, and AI + Biotech. The AI + CRO model is predominant, leveraging AI technology to provide outsourced drug development services [62][63]. - SaaS models face challenges due to limited market size and high competition, making them less favorable for new entrants [67]. Key Players and Competitive Landscape - The report highlights leading companies in the AI pharmaceutical space, including Insilico Medicine, Relay Therapeutics, and Schrodinger, which are involved in various stages of drug development [53][54]. - The competitive landscape is characterized by a "Matthew Effect," where leading players dominate due to their established capabilities and resources [6].

Investment Rating - The industry investment rating is "Strong Buy" [2]. Core Insights - The investment value of the AI+pharmaceutical industry lies in analyzing the current status and future potential of AI's role in drug development, focusing on efficiency and innovation [4]. - AI enhances drug development by reducing costs and increasing efficiency, particularly in the preclinical phase, where AI virtual screening significantly lowers the number of compounds needed for real trials, thus shortening development cycles and costs [5]. - The global market for AI-enabled drug development is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a CAGR of 22.6% [5]. - The industry is experiencing a structural differentiation trend in financing, with a total of $24.6 billion raised globally for AI+drug development since 2015, although there has been a decline in financing activity in 2022 due to economic downturns [48]. Summary by Sections AI's Role in Pharmaceuticals - AI in drug development combines technologies like NLP and deep learning to enhance efficiency and expand innovation space across the entire drug development process [9]. - AI's most mature applications are in preclinical research, where it can reduce costs by over 90% and significantly shorten development timelines [22]. High-Quality Data Production as Core Competitiveness - The ability to produce high-quality data is identified as a core competitive advantage in the industry, as it enables effective algorithm iteration and data accumulation [6]. - The industry faces challenges with "data silos," where high-quality data is scarce and not shared, making data production capabilities crucial for long-term competitiveness [6]. Market Size and Commercialization Focus - The AI+pharmaceutical financing landscape has seen rapid growth, with significant investments concentrated in the US and China, although the latter's share has decreased recently [48]. - The commercial focus is shifting towards molecular entities, with AI+CRO and AI+Biotech models emerging as dominant trends for revenue generation [58]. Business Models - The industry features three main business models: SaaS, AI+CRO, and AI+Biotech, with the latter two being more prevalent due to their higher revenue potential and lower risk exposure [63][67]. - SaaS models face challenges due to limited market size and high competition, suggesting that they may not be suitable for new entrants in the industry [67].

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]